Charles River And Deciphex Expand Partnership To Advance AI In Toxicologic Pathology

Charles River Laboratories, together with Deciphex, announced their next stage of strategic collaboration to improve image management and artificial intelligence (AI) tools dedicated to toxicologic pathology. Through their collaboration, these companies want to build a system that manages images with distribution and archiving features to enhance pathology workflow standards for efficiency and precise scalability.

Professor Julie Frearson, PhD, Corporate Senior Vice President, Chief Scientific Officer, Charles River, said in a statement, “Patholytix has transformed how we manage and analyze pathology data, enabling unprecedented efficiency and collaboration across our global teams. This next phase of our partnership with Deciphex marks a significant milestone in advancing digital workflows for non-clinical safety assessments.”

Deciphex has implemented its Patholytix platform as the foundation of this alliance to supply Charles River's worldwide histology laboratories and pathologists with sophisticated tools to handle secure data storage of toxicologic pathology information. Through its simplified digital method, this system cuts down processing delays while allowing teams nationwide to work without interruptions.  

“The exclusive integration of Patholytix into Charles River’s operations represents a transformative step in our mission to revolutionize digital pathology. This partnership exemplifies our commitment to delivering innovative solutions that enhance efficiency, drive collaboration, and ultimately accelerate safer drug discovery,” said Donal O’Shea, Chief Executive Officer of Deciphex.

The current partnership aims to expand the use of AI technology beyond the successful launch of Foresight in 2024. The partnership focuses on two development objectives: tissue analysis improvement and acute toxicity screening methods for carcinogenicity examinations.

Through their partnership, Deciphex and Charles River will boost drug development speed while enhancing decision quality and helping create medication therapies that better protect patients.